Beyond Standard Profiles: Why Custom Glycosylation Characterization is Non-Negotiable for Modern Biologics
The development of modern biologics demands a paradigm shift: glycosylation must be treated as a critical design parameter, not merely a compliance checkpoint. While standard analysis can list what glycans are present, it fails to uncover how they impact your drug's specific mechanism of action. This gap necessitates a purpose-driven, program-specific strategy—a concept central...